Apr 03, 2018
Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression
Jan 18, 2018
New Real World Evidence Shows that Long-acting Antipsychotics Reduce Risk of Mortality for Patients Living with Schizophrenia Compared to Oral Antipsychotics
Jan 11, 2018
Psychiatry's Brave New World--FDA Approves Digital Sensor in Antipsychotic Drug to Enforce Prescription Compliance
Jan 03, 2018
Landmark Schizophrenia Data That Bring Hope in Breaking the Cycle of Hospitalization and Incarceration Receive FDA Approval for Inclusion in INVEGA SUSTENNA® (paliperidone palmitate) Label
Dec 18, 2017
Allergan and Richter Announce Positive Topline Results from Phase 3 Study of Cariprazine for the Treatment of Bipolar I Depression
Dec 12, 2017
Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot
Nov 21, 2017
Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda(R) (Lurasidone Hydrochloride) in Europe
Nov 14, 2017
Otsuka And Proteus® Announce The First U.S. FDA Approval Of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
Nov 13, 2017
FDA approves pill with sensor that digitally tracks if patients have ingested their medication
Nov 13, 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Nov 10, 2017
Rising Competition for Treating Positive Symptoms of Schizophrenia Requires Companies to Focus on Therapies for Negative and Cognitive Symptoms
Nov 08, 2017
Schizophrenia Drugs Market Worth $7.9 Billion by 2022 | CAGR: 2.5%: Grand View Research, Inc.
Sep 22, 2017
Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia